The 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from June 3-7, 2016. The age of immunotherapies was on full display as numerous key presentations featured new immune therapies in development, evaluations of combination treatments, and biomarker development.

Key areas of interest included a push to develop PD-1 biomarkers to better identify likely responders, continued advancement in mutational subgroups for breast and lung cancers, and a plethora of early-stage developmental therapeutics. Interestingly, while ASCO is typically focused on solid tumors, there were several high-profile sessions on hematologic cancers which likely reflected the impending arrival of the first CAR-T immunotherapies. Also notable was much less discussion on pricing which was heavily featured at last year’s meeting. There were some presentations on the development of ASCO’s own metric for evaluating drug value, but they were generally low profile.

This post-meeting report features summaries of a few key topics along with commentary from our analysts on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting, for not only drugs but devices and diagnostics as well from our sister product, Meddevicetracker.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.